Literature DB >> 28176468

Correlation of pre-operative plasma protein concentrations in cardiac surgery patients with bleeding outcomes using a targeted quantitative proteomics approach.

Nathan Clendenen1, Ashley Tollefson1,2, Monika Dzieciatkowska3, Alice Cambiaghi4, Manuela Ferrario4, Miranda Kroehl5, Anirban Banerjee6, Angelo D'Alessandro3, Kirk C Hansen3, Nathaen Weitzel1.   

Abstract

PURPOSE: Despite recent advancements in the use of thrombelastography (TEG) in the surgical setting, adequate technology to accurately predict bleeding phenotypes for patients undergoing cardiopulmonary bypass on the basis of non-mechanical parameters is lacking. While basic science and translational studies have provided key mechanistic insights about the protein components of coagulation cascades and regulatory mediators of hemostasis and fibrinolysis, targeted protein assays are still missing and the association of protein profiles to bleeding phenotypes and TEG readouts have yet to be discovered.
OBJECTIVE: To identify protein biomarkers of bleeding phenotypes of cardiopulmonary bypass patients in pre-operative plasma. EXPERIMENTAL
DESIGN: We applied a targeted proteomics approach to quantify 123 plasma proteins from 23 patients undergoing cardiopulmonary bypass (CPB) and sternotomy. We then correlated these measurements to bleeding outcomes and TEG parameters, associated with speed of clot formation and strength.
RESULTS: In this pilot study, we demonstrate the feasibility of protein quantitation as a viable strategy to predict low versus high bleeding phenotypes (loss of < or > than 20% of estimated blood volume, calculated as 70 mL/kg for BMI<29.9, 60 mL/kg for BMI = 30-39.9, and 50 mL/kg for BMI>40. Statistical elaborations highlighted a core set of proteins showing significant correlations to either total blood loss or TEG R/MA parameters. CONCLUSION AND CLINICAL RELEVANCE: Though prospective verification and validation in larger cohorts will be necessary, this report suggests a potential for targeted quantitative proteomics of pre-operative plasma protein concentrations in the prediction of estimated blood loss following CPB.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Bleeding outcomes; Cardiopulmonary bypass surgery; Coagulation cascade; Medical proteomics; Targeted proteomics

Mesh:

Substances:

Year:  2017        PMID: 28176468      PMCID: PMC5985972          DOI: 10.1002/prca.201600175

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  42 in total

1.  Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters.

Authors:  Matthew R Russell; Brahim Achour; Edward A Mckenzie; Ruth Lopez; Matthew D Harwood; Amin Rostami-Hodjegan; Jill Barber
Journal:  J Proteome Res       Date:  2013-10-31       Impact factor: 4.466

Review 2.  An update on red blood cell storage lesions, as gleaned through biochemistry and omics technologies.

Authors:  Angelo D'Alessandro; Anastasios G Kriebardis; Sara Rinalducci; Marianna H Antonelou; Kirk C Hansen; Issidora S Papassideri; Lello Zolla
Journal:  Transfusion       Date:  2014-08-06       Impact factor: 3.157

3.  Point of care testing and cardiac surgery 2014.

Authors:  Nathaen S Weitzel
Journal:  J Cardiothorac Vasc Anesth       Date:  2014-04       Impact factor: 2.628

4.  Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients.

Authors:  G J Despotis; K S Filos; T N Zoys; C W Hogue; E Spitznagel; D G Lappas
Journal:  Anesth Analg       Date:  1996-01       Impact factor: 5.108

5.  Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery.

Authors:  L Shore-Lesserson; H E Manspeizer; M DePerio; S Francis; F Vela-Cantos; M A Ergin
Journal:  Anesth Analg       Date:  1999-02       Impact factor: 5.108

6.  Costs of excessive postoperative hemorrhage in cardiac surgery.

Authors:  Michael C Christensen; Stephan Krapf; Angela Kempel; Christian von Heymann
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-19       Impact factor: 5.209

Review 7.  Management of hemorrhage in cardiothoracic surgery.

Authors:  Klaus Görlinger; Linda Shore-Lesserson; Daniel Dirkmann; Alexander A Hanke; Niels Rahe-Meyer; Kenichi A Tanaka
Journal:  J Cardiothorac Vasc Anesth       Date:  2013-08       Impact factor: 2.628

8.  Lymph is not a plasma ultrafiltrate: a proteomic analysis of injured patients.

Authors:  Monika Dzieciatkowska; Angelo D'Alessandro; Ernest E Moore; Max Wohlauer; Anirban Banerjee; Christopher C Silliman; Kirk C Hansen
Journal:  Shock       Date:  2014-12       Impact factor: 3.454

9.  Multiplexed absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes.

Authors:  Julie M Pratt; Deborah M Simpson; Mary K Doherty; Jenny Rivers; Simon J Gaskell; Robert J Beynon
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

10.  Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers.

Authors:  Zhaojing Meng; Timothy D Veenstra
Journal:  Proteomics Clin Appl       Date:  2007-07-13       Impact factor: 3.494

View more
  2 in total

1.  Identification of Plasma Proteome Signatures Associated With Surgery Using SOMAscan.

Authors:  Tamara G Fong; Noel Y Chan; Simon T Dillon; Wenxiao Zhou; Bridget Tripp; Long H Ngo; Hasan H Otu; Sharon K Inouye; Sarinnapha M Vasunilashorn; Zara Cooper; Zhongcong Xie; Edward R Marcantonio; Towia A Libermann
Journal:  Ann Surg       Date:  2021-04-01       Impact factor: 12.969

2.  Pathologic Shear and Elongation Rates Do Not Cause Cleavage of Von Willebrand Factor by ADAMTS13 in a Purified System.

Authors:  Maria Bortot; Alireza Sharifi; Katrina Ashworth; Faye Walker; Allaura Cox; Katherine Ruegg; Nathan Clendenen; Keith B Neeves; David Bark; Jorge Di Paola
Journal:  Cell Mol Bioeng       Date:  2020-07-17       Impact factor: 2.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.